Invion Ltd Asset Resilience Ratio

Latest as of June 2025: 8.96%

Invion Ltd asset resilience ratio. Invion Ltd (IVX) has an Asset Resilience Ratio of 8.96% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IVX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$850.37K
≈ $601.69K USD Cash + Short-term Investments

Total Assets

AU$9.49 Million
≈ $6.71 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Invion Ltd (2002–2022)

Asset resilience ratio of Invion Ltd from 2002 to 2022. This chart shows how Invion Ltd's Asset Resilience Ratio has changed over time. Read Invion Ltd (IVX) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Invion Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IVX total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$850.37K 8.96%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$850.37K 8.96%

Asset Resilience Insights

  • Limited Liquidity: Invion Ltd maintains only 8.96% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Invion Ltd Industry Peers by Asset Resilience Ratio

Compare Invion Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 29.37%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Shenzhen Chipscreen Biosciences Co
SHG:688321
Drug Manufacturers - Specialty & Generic 5.10%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
Drug Manufacturers - Specialty & Generic 0.00%

Invion Ltd Asset Resilience Ratio by Year (2002–2022)

Invion Ltd asset resilience ratio by year from 2002 to 2022. The table below shows the annual Asset Resilience Ratio data for Invion Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-06-30 42.28% AU$8.47 Million
≈ $6.00 Million
AU$20.04 Million
≈ $14.18 Million
+23.90pp
2021-06-30 18.38% AU$1.04 Million
≈ $733.62K
AU$5.64 Million
≈ $3.99 Million
+2.59pp
2017-06-30 15.79% AU$917.49K
≈ $649.18K
AU$5.81 Million
≈ $4.11 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$11.98 Million
≈ $8.48 Million
--
2007-06-30 42.43% AU$1.58 Million
≈ $1.12 Million
AU$3.74 Million
≈ $2.64 Million
-29.52pp
2002-06-30 71.95% AU$1.07 Million
≈ $754.97K
AU$1.48 Million
≈ $1.05 Million
--
pp = percentage points

About Invion Ltd

AU:IVX Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.06 Million
AU$2.91 Million AUD
Market Cap Rank
#29988 Global
#1728 in Australia
Share Price
AU$0.03
Change (1 day)
-8.11%
52-Week Range
AU$0.03 - AU$0.10
All Time High
AU$4.80
About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more